{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:42:53Z","timestamp":1792608173967,"version":"4.5.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40265-022-01785-1","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T13:03:57Z","timestamp":1666271037000},"page":"1453-1468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-1478","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Mart\u00ednez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2121-7554","authenticated-orcid":false,"given":"Grace","family":"Oscullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garc\u00eda-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5113-9235","authenticated-orcid":false,"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5040","authenticated-orcid":false,"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"issue":"3","key":"1785_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","volume":"10","author":"S Aliberti","year":"2022","unstructured":"Aliberti S, Goeminne PC, O\u2019Donnell AE, Aksamit TR, Al-Jahdali H, Barker AF, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med. 2022;10(3):298\u2013306.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1785_CR2","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1513\/AnnalsATS.201507-472OC","volume":"12","author":"S Lonni","year":"2015","unstructured":"Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non-cystic fbrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc. 2015;12(12):1764\u201370.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"1785_CR3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.arbres.2019.12.021","volume":"57","author":"MA Martinez-Garc\u00eda","year":"2021","unstructured":"Martinez-Garc\u00eda MA, Villa C, Dobarganes Y, Gir\u00f3n R, Ma\u00edz L, Garc\u00eda-Clemente M, Sibila O, et al. RIBRON: The Spanish Online Bronchiectasis Registry. Characterization of the first 1912 patients. Arch Bronconeumol. 2021;57(1):28\u201335.","journal-title":"Arch Bronconeumol"},{"issue":"9","key":"1785_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2213-2600(18)30053-5","volume":"6","author":"JD Chalmers","year":"2018","unstructured":"Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respir Med. 2018;6(9):715\u201326.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1785_CR5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.00069007","volume":"31","author":"S Fuschillo","year":"2008","unstructured":"Fuschillo S, de Felice A, Balzano G. Mucosal infammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J. 2008;31(2):396\u2013406.","journal-title":"Eur Respir J"},{"issue":"10","key":"1785_CR6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.arbr.2020.06.003","volume":"56","author":"MA Martinez-Garcia","year":"2020","unstructured":"Martinez-Garcia MA, Posadas T, Sotgiu G, Blasi F, Saderi L, Aliberti S. Repeatability of circulating eosinophil measures and inhaled corticosteroids effect in bronchiectasis. A post hoc analysis of a randomized clinical trial. Arch Bronconeumol (Engl Ed). 2020;56(10):681\u20133.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"8","key":"1785_CR7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","volume":"205","author":"A Shoemark","year":"2022","unstructured":"Shoemark A, Shteinberg M, De Soyza A, Haworth C, Richardson H, Gao Y, et al. Characterisation of eosinophilic bronchiectasis: a European multicohort study. Am J Respir Crit Care Med. 2022;205(8):894\u2013902.","journal-title":"Am J Respir Crit Care Med"},{"key":"1785_CR8","first-page":"671","volume":"57","author":"MA Martinez-Garcia","year":"2021","unstructured":"Martinez-Garcia MA. Bronchiectasis and eosinophils. Arch Bronconeumol. 2021;57:671\u20132.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"1785_CR9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.arbres.2019.04.017","volume":"56","author":"E Mons\u00f3","year":"2020","unstructured":"Mons\u00f3 E. Look at the wood and not at the tree: the microbiome in chronic obstructive lung disease and cystic fibrosis. Arch Bronconeumol. 2020;56(1):5\u20136.","journal-title":"Arch Bronconeumol"},{"key":"1785_CR10","first-page":"6","volume":"147","author":"PJ Cole","year":"1986","unstructured":"Cole PJ. Inflammation: a two-edged sword\u2014the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6\u201315.","journal-title":"Eur J Respir Dis Suppl"},{"issue":"1","key":"1785_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.arbres.2019.12.017","volume":"57","author":"T Posadas","year":"2021","unstructured":"Posadas T, Oscullo G, Zaldivar E, Villa C, Dobarganes Y, Gir\u00f3n R, et al. C-reactive protein concentration in steady-state bronchiectasis: prognostic value of future severe exacerbations. Data from the Spanish Registry of Bronchiectasis (RIBRON). Arch Bronconeumol. 2021;57(1):21\u20137.","journal-title":"Arch Bronconeumol"},{"key":"1785_CR12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2017.04.009","volume":"127","author":"AD Saleh","year":"2017","unstructured":"Saleh AD, Chalmers JD, De Soyza A, Fardon TC, Koustas SO, Scott J. The heterogeneity of systemic inflammation in bronchiectasis. Respir Med. 2017;127:33\u20139.","journal-title":"Respir Med"},{"issue":"10","key":"1785_CR13","first-page":"621","volume":"56","author":"CL Chen","year":"2020","unstructured":"Chen CL, Huang Y, Yuan JJ, Li HM, Han XR, Martinez-Garcia MA, et al. The Roles of bacteria and viruses in bronchiectasis exacerbation: a prospective study. Arch Bronconeumol. 2020;56(10):621\u20139.","journal-title":"Arch Bronconeumol"},{"key":"1785_CR14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2147\/COPD.S132961","volume":"12","author":"MA Martinez-Garcia","year":"2017","unstructured":"Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis. 2017;12:1401\u201311.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1785_CR15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1159\/000507228","volume":"99","author":"C Crimi","year":"2020","unstructured":"Crimi C, Ferri S, Campisi R, Crimi N. The link between asthma and bronchiectasis: state of the art. Respiration. 2020;99:463\u201376.","journal-title":"Respiration"},{"issue":"3","key":"1785_CR16","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.","journal-title":"Eur Respir J"},{"issue":"2","key":"1785_CR17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbres.2017.07.016","volume":"54","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2018","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, M\u00e1iz L, Olveira C, Gir\u00f3n RM, de la Rosa D, Blanco M, et al. Spanish guidelines on treatment of bronchiectasis in adults. Arch Bronconeumol. 2018;54(2):88\u201398.","journal-title":"Arch Bronconeumol"},{"issue":"Suppl 1","key":"1785_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","volume":"74","author":"AT Hill","year":"2019","unstructured":"Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1\u201369.","journal-title":"Thorax"},{"issue":"58","key":"1785_CR19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.arbres.2021.10.003","volume":"2022","author":"HK Reddel","year":"2022","unstructured":"Reddel HK, Bacharier LB, Bateman ED, Brighting CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma strategy 2021. Executive summary and rationale for key changes. Arch Bronconeumol. 2022;2022(58):35\u201351.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"1785_CR20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.arbres.2020.10.003","volume":"57","author":"V Plaza","year":"2022","unstructured":"Plaza V, Blanco M, Garc\u00eda G, Korta J, Molina J, Quirce S. Highlights of the Spanish Asthma Guidelines (GEMA), version 5.0. Arch Bronconeumol. 2022;57(1):11\u20132.","journal-title":"Arch Bronconeumol"},{"key":"1785_CR21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.arbr.2019.10.009","volume":"56","author":"V Plaza","year":"2020","unstructured":"Plaza V, G\u00f3mez-Outes A, Quirce S, Alobid I, \u00c1lvarez C, Blanco M, et al. Discrepancies between GEMA and GINA in the classification of inhaled corticosteroids. Arch Bronconeumol. 2020;56:472\u20133.","journal-title":"Arch Bronconeumol"},{"issue":"5 Pt 1","key":"1785_CR22","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1164\/ajrccm.158.5.9804028","volume":"158","author":"E Pizzichini","year":"1998","unstructured":"Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1511\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9240","key":"1785_CR23","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(00)02872-5","volume":"356","author":"CE Brightling","year":"2000","unstructured":"Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480\u20135.","journal-title":"Lancet"},{"issue":"3","key":"1785_CR24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/thx.2004.032516","volume":"60","author":"CE Brightling","year":"2005","unstructured":"Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193\u20138.","journal-title":"Thorax"},{"issue":"6","key":"1785_CR25","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","volume":"184","author":"M Bafadhel","year":"2011","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662\u201371.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1785_CR26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000330667","volume":"83","author":"M Bafadhel","year":"2012","unstructured":"Bafadhel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2012;83(1):36\u201344.","journal-title":"Respiration"},{"key":"1785_CR27","unstructured":"The Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2022. Available at: https:\/\/goldcopd.org\/. Accessed 30 May 2022."},{"issue":"1","key":"1785_CR28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.arbres.2021.03.005","volume":"58","author":"M Miravitlles","year":"2022","unstructured":"Miravitlles M, Calle M, Molina J, Almagro P, Tom\u00e1s G\u00f3mez J, Trigueros JA, et al. Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):69\u201381.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"1785_CR29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.arbres.2020.08.002","volume":"57","author":"M Miravitlles","year":"2021","unstructured":"Miravitlles M, Calle M, Soler-Catalu\u00f1a JJ. GesEPOC 2021: One more step towards personalized treatment of COPD. Arch Bronconeumol. 2021;57(1):9\u201310.","journal-title":"Arch Bronconeumol"},{"key":"1785_CR30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/thx.53.8.685","volume":"53","author":"M Gaga","year":"1998","unstructured":"Gaga M, Bentley AM, Humbert M, Barkans J, O\u2019Brien F, Wathen CG, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax. 1998;53:685\u201391.","journal-title":"Thorax"},{"key":"1785_CR31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thorax.57.1.15","volume":"57","author":"J Angrill","year":"2022","unstructured":"Angrill J, Agust\u00ed C, de Celis R, Ra\u00f1\u00f3 A, Gonzalez J, Sol\u00e9 T. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2022;57:15\u20139.","journal-title":"Thorax"},{"key":"1785_CR32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/resp.12582","volume":"20","author":"WJ Guan","year":"2015","unstructured":"Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Gu YY. Sputum matrix metalloproteinase-8 and -9 and tissue inhibitor of metalloproteinase-1 in bronchiectasis: clinical correlates and prognostic implications. Respirology. 2015;20:1073\u201381.","journal-title":"Respirology"},{"key":"1785_CR33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1146\/annurev-pathol-012615-044344","volume":"11","author":"RJ Boyton","year":"2016","unstructured":"Boyton RJ, Altmann DM. Bronchiectasis: current concepts in pathogenesis, immunology, and microbiology. Annu Rev Pathol. 2016;11:523\u201354.","journal-title":"Annu Rev Pathol"},{"key":"1785_CR34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/COPD.S6133","volume":"4","author":"PT King","year":"2009","unstructured":"King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1785_CR35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cyto.2017.08.005","volume":"99","author":"S Tsikrika","year":"2017","unstructured":"Tsikrika S, Dimakou K, Papaioannou AI, Hillas G, Thanos L, Kostikas K, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine. 2017;99:281\u20136.","journal-title":"Cytokine"},{"key":"1785_CR36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12016-015-8525-4","volume":"50","author":"KA Ravin","year":"2016","unstructured":"Ravin KA, Loy M. The eosinophil in infection. Clin Rev Allerg Immunol. 2016;50:214\u201327.","journal-title":"Clin Rev Allerg Immunol."},{"key":"1785_CR37","first-page":"341","volume":"6","author":"PT King","year":"2010","unstructured":"King PT, Daviskas E. Pathogenesis and diagnosis of bronchiectasis. Breathe. 2010;6:341\u201351.","journal-title":"Breathe"},{"issue":"10","key":"1785_CR38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.arbres.2020.04.023","volume":"56","author":"CD de la Rosa","year":"2020","unstructured":"de la Rosa CD, L\u00f3pez-Campos JL, Alc\u00e1zar Navarrete B, Calle Rubio M, Cant\u00f3n Moreno R, Garc\u00eda-Rivero JL, et al. Consensus document on the diagnosis and treatment of chronic bronchial Infection in chronic obstructive pulmonary disease. Arch Bronconeumol. 2020;56(10):651\u201364.","journal-title":"Arch Bronconeumol"},{"issue":"10150","key":"1785_CR39","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","volume":"392","author":"PA Flume","year":"2018","unstructured":"Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392(10150):880\u201390.","journal-title":"Lancet"},{"issue":"1","key":"1785_CR40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.arbres.2021.03.009","volume":"58","author":"D De la Rosa","year":"2022","unstructured":"De la Rosa D, Martinez-Garcia MA, Barreiro E, Tabernero E, Costa R, Garcia-Clemente M, et al. Effectiveness and safety of inhaled antibiotics in patients with chronic obstructive pulmonary disease. A multicentre observational study. Arch Bronconeumol. 2022;58(1):11\u201321.","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"1785_CR41","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-021-01289-7","volume":"27","author":"M Mac Aog\u00e1in","year":"2021","unstructured":"Mac Aog\u00e1in M, Narayana JK, Tiew PY, Ali NABM, Yong VFL, Jaggi TK, et al. Integrative microbiomics in bronchiectasis exacerbations. Nat Med. 2021;27(4):688\u201399.","journal-title":"Nat Med"},{"key":"1785_CR42","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0048-2019","volume":"28","author":"H Richardson","year":"2019","unstructured":"Richardson H, Dicker AJ, Barclay H, Chalmers JD. The microbiome in bronchiectasis. Eur Respir Rev. 2019;28: 190048.","journal-title":"Eur Respir Rev"},{"issue":"2","key":"1785_CR43","doi-asserted-by":"crossref","first-page":"1701953","DOI":"10.1183\/13993003.01953-2017","volume":"51","author":"D Ara\u00fajo","year":"2018","unstructured":"Ara\u00fajo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018;51(2):1701953.","journal-title":"Eur Respir J"},{"issue":"11","key":"1785_CR44","first-page":"1602","volume":"12","author":"S Finch","year":"2015","unstructured":"Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602\u201311.","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"1785_CR45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","volume":"189","author":"JD Chalmers","year":"2014","unstructured":"Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576\u201385.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1785_CR46","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","volume":"132","author":"MA Mart\u00ednez-Garc\u00eda","year":"2007","unstructured":"Mart\u00ednez-Garc\u00eda MA, Soler-Catalu\u00f1a JJ, Perpi\u00f1\u00e1-Tordera M, Rom\u00e1n-S\u00e1nchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565\u201372.","journal-title":"Chest"},{"issue":"9","key":"1785_CR47","doi-asserted-by":"crossref","first-page":"e1269","DOI":"10.1016\/S2214-109X(19)30327-4","volume":"7","author":"R Dhar","year":"2019","unstructured":"Dhar R, Singh S, Talwar D, Mohan M, Kant Tripathi S, Swarnakar R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Glob Health. 2019;7(9):e1269\u201379.","journal-title":"Lancet Glob Health"},{"key":"1785_CR48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/COPD.S121943","volume":"12","author":"MA Martinez-Garcia","year":"2017","unstructured":"Martinez-Garcia MA, Athanazio RA, Gir\u00f3n R, M\u00e1iz-Carro L, de la Rosa D, Olveira C, et al. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon Dis. 2017;12:275\u201384.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1785_CR49","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","volume":"15","author":"TR Aksamit","year":"2017","unstructured":"Aksamit TR, O\u2019Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Bronchiectasis Research Registry Consortium. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;15:982\u201392.","journal-title":"Chest"},{"issue":"4","key":"1785_CR50","first-page":"C002162","volume":"2001","author":"T Lasserson","year":"2001","unstructured":"Lasserson T, Holt K, Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev. 2001;2001(4):C002162.","journal-title":"Cochrane Database Syst Rev"},{"key":"1785_CR51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/164_2016_62","volume":"237","author":"PJ Barnes","year":"2017","unstructured":"Barnes PJ. Glucocorticosteroids. Handb Exp Pharmacol. 2017;237:93\u2013115.","journal-title":"Handb Exp Pharmacol"},{"key":"1785_CR52","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.100969","volume":"85","author":"G Caramori","year":"2022","unstructured":"Caramori G, Nucera F, Mumby S, Lo Bello F, Adcock IM. Corticosteroid resistance in asthma: cellular and molecular mechanisms. Mol Aspects Med. 2022;85: 100969.","journal-title":"Mol Aspects Med"},{"issue":"1\u20132","key":"1785_CR53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mce.2013.01.026","volume":"380","author":"C Strehl","year":"2013","unstructured":"Strehl C, Buttgereit F. Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol Cell Endocrinol. 2013;380(1\u20132):32\u201340.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"1785_CR54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/me.2008-0283","volume":"23","author":"K De Bosscher","year":"2009","unstructured":"De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol. 2009;23(3):281\u201391.","journal-title":"Mol Endocrinol"},{"issue":"1","key":"1785_CR55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pharmthera.2011.12.004","volume":"134","author":"AR Clark","year":"2012","unstructured":"Clark AR, Belvisi MG. Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther. 2012;134(1):54\u201367.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1785_CR56","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","volume":"40","author":"RA Panettieri","year":"2019","unstructured":"Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci. 2019;40(1):38\u201349.","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"1785_CR57","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/thoraxjnl-2013-203773","volume":"68","author":"I Sabroe","year":"2013","unstructured":"Sabroe I, Postma D, Heijink I, Dockrell DH. The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax. 2013;68(12):1085\u20137.","journal-title":"Thorax"},{"key":"1785_CR58","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/164_2016_98","volume":"237","author":"IM Adcock","year":"2017","unstructured":"Adcock IM, Mumby S. Glucocorticoids. Handb Exp Pharmacol. 2017;237:171\u201396.","journal-title":"Handb Exp Pharmacol"},{"issue":"10","key":"1785_CR59","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1164\/rccm.202109-2024ED","volume":"204","author":"S Singh","year":"2021","unstructured":"Singh S, Pragman AA, Segal LN. Balancing benefits and risks: do inhaled corticosteroids modify the lung microbiome? Am J Respir Crit Care Med. 2021;204(10):1117\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"1785_CR60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/thx.2002.001586","volume":"59","author":"S O'Sullivan","year":"2004","unstructured":"O\u2019Sullivan S, Cormican L, Burke CM, Poulter LW. Fluticasone induces T cell apoptosis in the bronchial wall of mild to moderate asthmatics. Thorax. 2004;59(8):657\u201361.","journal-title":"Thorax"},{"issue":"1","key":"1785_CR61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1465-9921-7-53","volume":"7","author":"IK Demedts","year":"2006","unstructured":"Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res. 2006;7(1):53.","journal-title":"Respir Res"},{"issue":"1","key":"1785_CR62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4049\/jimmunol.1402217","volume":"195","author":"VR Stolberg","year":"2015","unstructured":"Stolberg VR, McCubbrey AL, Freeman CM, Brown JP, Crudgington SW, Taitano SH, et al. Glucocorticoid-augmented efferocytosis inhibits pulmonary pneumococcal clearance in mice by reducing alveolar macrophage bactericidal function. J Immunol. 2015;195(1):174\u201384.","journal-title":"J Immunol"},{"issue":"10","key":"1785_CR63","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/biomedicines9101312","volume":"9","author":"HR Keir","year":"2021","unstructured":"Keir HR, Contoli M, Chalmers JD. Inhaled corticosteroids and the lung microbiome in COPD. Biomedicines. 2021;9(10):1312.","journal-title":"Biomedicines."},{"issue":"1","key":"1785_CR64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thorax.57.1.15","volume":"57","author":"J Angrill","year":"2002","unstructured":"Angrill J, Agust\u00ed C, de Celis R, Ra\u00f1\u00f3 A, Gonzalez J, Sol\u00e9 T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57(1):15\u20139.","journal-title":"Thorax"},{"issue":"3","key":"1785_CR65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/thx.2002.003236","volume":"60","author":"KW Tsang","year":"2005","unstructured":"Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60(3):239\u201343.","journal-title":"Thorax"},{"issue":"3","key":"1785_CR66","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcp.12637","volume":"80","author":"PT Daley-Yates","year":"2015","unstructured":"Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372\u201380.","journal-title":"Br J Clin Pharmacol"},{"key":"1785_CR67","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101828","volume":"58","author":"MG Matera","year":"2019","unstructured":"Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulm Pharmacol Ther. 2019;58: 101828.","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"1785_CR68","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1183\/09031936.00074905","volume":"28","author":"H Derendorf","year":"2006","unstructured":"Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042\u201350.","journal-title":"Eur Respir J"},{"issue":"4","key":"1785_CR69","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1513\/pats.200403-025MS","volume":"1","author":"J Winkler","year":"2004","unstructured":"Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356\u201363.","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"1785_CR70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pupt.2005.10.008","volume":"20","author":"GA Rossi","year":"2007","unstructured":"Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther. 2007;20(1):23\u201335.","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"1785_CR71","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1345\/aph.1L546","volume":"43","author":"HW Kelly","year":"2009","unstructured":"Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother. 2009;43(3):519\u201327.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1785_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s41030-017-0043-5","volume":"3","author":"Q Ye","year":"2017","unstructured":"Ye Q, He XO, D\u2019Urzo A. A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulm Ther. 2017;3(1):1\u201318.","journal-title":"Pulm Ther."},{"issue":"3","key":"1785_CR73","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.iac.2005.05.004","volume":"25","author":"M H\u00fcbner","year":"2005","unstructured":"H\u00fcbner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25(3):469\u201388.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"1785_CR74","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1208\/s12248-015-9760-6","volume":"17","author":"JM Borghardt","year":"2015","unstructured":"Borghardt JM, Weber B, Staab A, Kloft C. Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs. AAPS J. 2015;17(4):853\u201370.","journal-title":"AAPS J"},{"issue":"1 Pt 2","key":"1785_CR75","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0091-6749(96)80217-X","volume":"97","author":"M Johnson","year":"1996","unstructured":"Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol. 1996;97(1 Pt 2):169\u201376.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1785_CR76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1465-9921-6-21","volume":"6","author":"M Freiwald","year":"2005","unstructured":"Freiwald M, Valotis A, Kirschbaum A, McClellan M, M\u00fcrdter T, Fritz P, et al. Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. Respir Res. 2005;6(1):21.","journal-title":"Respir Res"},{"issue":"4","key":"1785_CR77","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S1081-1206(10)61677-8","volume":"91","author":"HW Kelly","year":"2003","unstructured":"Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91(4):326\u201334.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1785_CR78","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/clpt.2014.27","volume":"95","author":"P B\u00e4ckman","year":"2014","unstructured":"B\u00e4ckman P, Adelmann H, Petersson G, Jones CB. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Ther. 2014;95(5):509\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1785_CR79","first-page":"623","volume":"26","author":"A Miller-Larsson","year":"1998","unstructured":"Miller-Larsson A, Mattsson H, Hjertberg E, Dahlb\u00e4ck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998;26(7):623\u201330.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1785_CR80","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.pupt.2005.02.012","volume":"18","author":"R Nave","year":"2005","unstructured":"Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2005;18(6):390\u20136.","journal-title":"Pulm Pharmacol Ther"},{"issue":"3 Suppl","key":"1785_CR81","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0091-6749(03)01859-1","volume":"112","author":"DB Allen","year":"2003","unstructured":"Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112(3 Suppl):S1\u201340.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1785_CR82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40262-012-0021-x","volume":"52","author":"A Allen","year":"2013","unstructured":"Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013;52(1):37\u201342.","journal-title":"Clin Pharmacokinet"},{"key":"1785_CR83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2172-14-7","volume":"14","author":"P Wang","year":"2013","unstructured":"Wang P, Wang X, Yang X, Liu Z, Wu M, Li G. Budesonide suppresses pulmonary antibacterial host defense by down-regulating cathelicidin-related antimicrobial peptide in allergic inflammation mice and in lung epithelial cells. BMC Immunol. 2013;14:7.","journal-title":"BMC Immunol"},{"issue":"2","key":"1785_CR84","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1034\/j.1399-3003.1999.14b21.x","volume":"14","author":"RB Dowling","year":"1999","unstructured":"Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J. 1999;14(2):363\u20139.","journal-title":"Eur Respir J"},{"issue":"9","key":"1785_CR85","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.rmed.2005.12.002","volume":"100","author":"MA Mart\u00ednez-Garc\u00eda","year":"2006","unstructured":"Mart\u00ednez-Garc\u00eda MA, Perpi\u00f1\u00e1-Tordera M, Rom\u00e1n-S\u00e1nchez P, Soler-Catalu\u00f1a JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100(9):1623\u201332.","journal-title":"Respir Med"},{"issue":"4","key":"1785_CR86","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s11096-012-9659-6","volume":"34","author":"R Hernando","year":"2012","unstructured":"Hernando R, Drobnic ME, Cruz MJ, Ferrer A, Su\u00f1\u00e9 P, Montoro JB, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm. 2012;34(4):644\u201350.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"1785_CR87","first-page":"CD000996","volume":"5","author":"N Kapur","year":"2018","unstructured":"Kapur N, Petsky HL, Bell S, Kolbe J, Chang AB. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst Rev. 2018;5(5):CD000996.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1785_CR88","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1164\/ajrccm.158.3.9710090","volume":"158","author":"KW Tsang","year":"1998","unstructured":"Tsang KW, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158(3):723\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1785_CR89","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2147\/COPD.S311236","volume":"16","author":"KEJ H\u00e5kansson","year":"2021","unstructured":"H\u00e5kansson KEJ, Fjaellegaard K, Browatzki A, D\u00f6nmez Sin M, Ulrik CS. Inhaled corticosteroid therapy in bronchiectasis is associated with all-cause mortality: a prospective cohort study. Int J Chron Obstruct Pulmon Dis. 2021;16:2119\u201327.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"1785_CR90","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.chest.2017.04.167","volume":"152","author":"E Henkle","year":"2017","unstructured":"Henkle E, Aksamit TR, Barker AF, Curtis JR, Daley CL, Anne Daniels ML, et al. Pharmacotherapy for non-cystic fibrosis bronchiectasis: results from an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. Chest. 2017;152(6):1120\u20137.","journal-title":"Chest"},{"key":"1785_CR91","first-page":"A6282","volume":"197","author":"E Henkel","year":"2018","unstructured":"Henkel E, Chan B, Aksamit TR, Curtis JR, Winthrop KL. Factors associated with extended inhaled corticosteroid use in US Medicare bronchiectasis patients. Am J Respir Crit Care Med. 2018;197:A6282.","journal-title":"Am J Respir Crit Care Med"},{"issue":"42","key":"1785_CR92","volume":"95","author":"P Wei","year":"2016","unstructured":"Wei P, Yang JW, Lu HW, Mao B, Yang WL, Xu JF. Combined inhaled corticosteroid and long-acting \u03b22-adrenergic agonist therapy for noncystic fibrosis bronchiectasis with airflow limitation: an observational study. Medicine (Baltimore). 2016;95(42): e5116.","journal-title":"Medicine (Baltimore)"},{"key":"1785_CR93","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1164\/ajrccm.158.3.9710031","volume":"168","author":"S Loukides","year":"1998","unstructured":"Loukides S, Horwarth I, Wodehouse T, Coler PJ, Barnes PJ. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med. 1998;168:991\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"1785_CR94","first-page":"1301","volume":"8","author":"KW Tsang","year":"2004","unstructured":"Tsang KW, Tan KC, Ho PL, Ooi GC, Khong PL, Leung R, et al. Exhaled nitric oxide in bronchiectasis: the effects of inhaled corticosteroid therapy. Int J Tuberc Lung Dis. 2004;8:1301\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1785_CR95","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s11096-012-9659-6","volume":"34","author":"R Hernando","year":"2012","unstructured":"Hernando R, Drobnic ME, Cruz MJ, Ferrer A, Su\u00f1e P, Montoro J, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm. 2012;34:644\u201350.","journal-title":"Int J Clin Pharm"},{"key":"1785_CR96","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106127","volume":"172","author":"MA Martinez-Garcia","year":"2020","unstructured":"Martinez-Garcia MA, Posadas T, Sotgiu G, Blasi F, Saderi L, Aliberti A. Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials. Resp Med. 2020;172: 106127.","journal-title":"Resp Med."},{"issue":"4","key":"1785_CR97","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003495-200969040-00002","volume":"69","author":"J Ilowite","year":"2009","unstructured":"Ilowite J, Spiegler P, Kessler H. Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents. Drugs. 2009;69(4):407\u201319.","journal-title":"Drugs"},{"key":"1785_CR98","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0954-6111(06)80227-1","volume":"86","author":"JS Elborn","year":"1992","unstructured":"Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varguese G. Inhaled steroids in patients with bronchiectasis. Respir Med. 1992;86:121\u20134.","journal-title":"Respir Med"},{"key":"1785_CR99","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.rmed.2005.12.002","volume":"100","author":"MA Martinez-Garcia","year":"2006","unstructured":"Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100:1623\u201332.","journal-title":"Respir Med"},{"issue":"4","key":"1785_CR100","first-page":"243","volume":"57","author":"JM Joshi","year":"2004","unstructured":"Joshi JM, Sundaram P. Role of inhaled steroids in stable bronchiectasis. Indian Pract. 2004;57(4):243\u20135.","journal-title":"Indian Pract"},{"key":"1785_CR101","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1378\/chest.11-0180","volume":"141","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2012","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Soler-Catalu\u00f1a JJ, Catal\u00e1n-Serra P, Rom\u00e1n-S\u00e1nchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141:461\u20138.","journal-title":"Chest"},{"key":"1785_CR102","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","volume":"168","author":"S Suissa","year":"2013","unstructured":"Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;168:1029\u201336.","journal-title":"Thorax"},{"key":"1785_CR103","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/thoraxjnl-2012-201772","volume":"68","author":"C Andrejak","year":"2013","unstructured":"Andrejak C, Nielsen R, Thomsen V\u00d8, Duhaut P, S\u00f8rensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68:256\u201362.","journal-title":"Thorax"},{"key":"1785_CR104","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/thoraxjnl-2021-217160","volume":"77","author":"J Ekl\u00f6f","year":"2022","unstructured":"Ekl\u00f6f J, Ingebrigtsen TS, Sorensen R, Isam Saeed M, Alispahic IA, Sivapalan P, et al. Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease. Thorax. 2022;77:573\u201380.","journal-title":"Thorax"},{"key":"1785_CR105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5588\/ijtld.13.0255","volume":"18","author":"JK Lee","year":"2014","unstructured":"Lee JK, Lee J, Park SS, Heo EY, Park YS, Lee CH, et al. Effect of inhalers on the development of haemoptysis in patients with non-cystic fibrosis bronchiectasis. Int J Tuberc Lung Dis. 2014;18:363\u201370.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1785_CR106","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1183\/09031936.00016908","volume":"32","author":"J Holme","year":"2008","unstructured":"Holme J, Tomlinson JW, Stockley RA, Steward PM, Barlow N, Sullivan AL. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Resp J. 2008;32:1047\u201352.","journal-title":"Eur Resp J."},{"issue":"10","key":"1785_CR107","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","volume":"7","author":"JD Chalmers","year":"2019","unstructured":"Chalmers JD, Boersma W, Lonergan M, Jayaram L, Crichton ML, Karalus N. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med. 2019;7(10):845\u201354.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1785_CR108","doi-asserted-by":"crossref","first-page":"1801896","DOI":"10.1183\/13993003.01896-2018","volume":"54","author":"E Henkle","year":"2019","unstructured":"Henkle E, Curtis JR, Chen L, Chan B, Aksamit TR, Daley CL, et al. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J. 2019;54(1):1801896.","journal-title":"Eur Respir J"},{"issue":"1","key":"1785_CR109","doi-asserted-by":"crossref","first-page":"00786","DOI":"10.1183\/23120541.00786-2020","volume":"8","author":"E Henkle","year":"2022","unstructured":"Henkle E, Daley CL, Curtis JR, Chan B, Aksamit TR, Winthrop KL. Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis. ERJ Open Res. 2022;8(1):00786\u20132020.","journal-title":"ERJ Open Res."},{"issue":"3","key":"1785_CR110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/atm.ATM_171_17","volume":"12","author":"H Al-Jahdali","year":"2017","unstructured":"Al-Jahdali H, Alshimemeri A, Mobeireek A, Albanna AS, Al Shirawi NN, Wali S, et al. The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. Ann Thorac Med. 2017;12(3):135\u201361.","journal-title":"Ann Thorac Med."},{"issue":"1","key":"1785_CR111","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5694\/mjac14.00287","volume":"202","author":"AB Chang","year":"2015","unstructured":"Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Thoracic Society of Australia and New Zealand guidelines. Med J Aust. 2015;202(1):130.","journal-title":"Med J Aust"},{"issue":"1","key":"1785_CR112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12931-018-0746-7","volume":"19","author":"A Padilla","year":"2018","unstructured":"Padilla A, Olveira C, Fernandez L, Marco I, Plata AJ, Alvarez A, et al. Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients. Respir Res. 2018;19(1):43.","journal-title":"Respir Res"},{"issue":"3","key":"1785_CR113","doi-asserted-by":"crossref","first-page":"1800328","DOI":"10.1183\/13993003.00328-2018","volume":"52","author":"E Polverino","year":"2018","unstructured":"Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, et al. The overlap between bronchiectasis and chronic airways diseases: state of the art and future directions. Eur Respir J. 2018;52(3):1800328.","journal-title":"Eur Respir J"},{"issue":"3","key":"1785_CR114","volume":"11","author":"Q Du","year":"2016","unstructured":"Du Q, Jin J, Liu X, Sun Y. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS ONE. 2016;11(3): e0150532.","journal-title":"PLoS ONE"},{"issue":"1","key":"1785_CR115","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/s41467-018-04574-1","volume":"9","author":"A Singanayagam","year":"2018","unstructured":"Singanayagam A, Glanville N, Girkin JL, Ching YM, Marcellini A, Porter JD, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun. 2018;9(1):2229.","journal-title":"Nat Commun"},{"issue":"6","key":"1785_CR116","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2019.12.907","volume":"146","author":"A Singanayagam","year":"2020","unstructured":"Singanayagam A, Johnston SL. Long-term impact of inhaled corticosteroid use in asthma and chronic obstructive pulmonary disease (COPD): Review of mechanisms that underlie risks. J Allergy Clin Immunol. 2020;146(6):1292\u20134.","journal-title":"J Allergy Clin Immunol"},{"issue":"507","key":"1785_CR117","doi-asserted-by":"crossref","first-page":"eaav3879","DOI":"10.1126\/scitranslmed.aav3879","volume":"11","author":"A Singanayagam","year":"2019","unstructured":"Singanayagam A, Glanville N, Cuthbertson L, Bartlett NW, Finney LJ, Turek E, et al. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Sci Transl Med. 2019;11(507):eaav3879.","journal-title":"Sci Transl Med."},{"issue":"8","key":"1785_CR118","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14656566.2022.2076592","volume":"23","author":"M Cazzola","year":"2022","unstructured":"Cazzola M, Ora J, Calzetta L, Rogliani P, Matera MG. Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? Expert Opin Pharmacother. 2022;23(8):917\u201327.","journal-title":"Expert Opin Pharmacother"},{"key":"1785_CR119","first-page":"1079","volume":"201","author":"MA Martinez-Garcia","year":"2020","unstructured":"Martinez-Garcia MA, Faner R, Oscullo G, de la Rosa D, Soler JJ, Ballester M, et al. Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease. A Network Analysis. Am J Respir Crit Care Med. 2020;201:1079\u201385.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1785_CR120","doi-asserted-by":"crossref","first-page":"2000453","DOI":"10.1183\/13993003.00453-2020","volume":"56","author":"S Aliberti","year":"2020","unstructured":"Aliberti S, Sotgiu G, Blasi F, Saderi L, Posadas T, Martinez-Garcia MA. Blood eosinophils predict inhaled fluticasone response in bronchiectasis. Eur Respir J. 2020;56(2):2000453.","journal-title":"Eur Respir J"},{"issue":"8","key":"1785_CR121","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.arbres.2022.01.014","volume":"58","author":"BG Cosio","year":"2022","unstructured":"Cosio BG, Shafiek H, Martinez-Garcia MA. Is it time to readjust the doses of inhaled corticosteroids in COPD? Arch Bronconeumol. 2022;58(8):593\u20134. https:\/\/doi.org\/10.1016\/j.arbres.2022.01.014.","journal-title":"Arch Bronconeumol"},{"key":"1785_CR122","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.rmed.2019.07.016","volume":"155","author":"SK Visser","year":"2019","unstructured":"Visser SK, Bye PTP, Fox GJ, Burr LD, Chang AB, et al. Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. Resp Med. 2019;155:97\u2013103.","journal-title":"Resp Med."},{"key":"1785_CR123","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/resp.14042","volume":"26","author":"H Lee","year":"2021","unstructured":"Lee H, Dhar R, Oh YM. Characteristics of bronchiectasis in Korea: First data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries. Respirology. 2021;26:618\u201320.","journal-title":"Respirology"},{"key":"1785_CR124","first-page":"OA1312","volume":"58","author":"E Polverino","year":"2021","unstructured":"Polverino E, Chalmers JD, Aliberti S, Haworth C, Blasi F, Boersma W, et al. Inhaled corticosteroids use in patients with bronchiectasis: Data from the EMBARC registry. Eur Resp J. 2021;58:OA1312.","journal-title":"Eur Resp J."},{"key":"1785_CR125","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/thorax.55.8.635","volume":"55","author":"C O\u2019Brien","year":"2000","unstructured":"O\u2019Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55:635\u201342.","journal-title":"Thorax"},{"issue":"1","key":"1785_CR126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40265-021-01646-3","volume":"82","author":"MA Martinez-Garcia","year":"2022","unstructured":"Martinez-Garcia MA, Oscullo G, Garcia-Ortega A, Matera MG, Rogliani P, Cazzola M. Rationale and clinical use of bronchodilators in adults with bronchiectasis. Drugs. 2022;82(1):1\u201313.","journal-title":"Drugs"},{"key":"1785_CR127","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.arbres.2020.07.032","volume":"57","author":"M Monteagudo","year":"2021","unstructured":"Monteagudo M, Nu\u00f1ez A, Solntseva I, Dhalwani N, Booth A, Barrecheguren M, et al. Treatment pathways before and after triple therapy in COPD: a population-based study in primary care in Spain. Arch Bronconeumol. 2021;57:205\u201313.","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"1785_CR128","first-page":"242","volume":"56","author":"JL L\u00f3pez-Campos","year":"2020","unstructured":"L\u00f3pez-Campos JL, Carrasco-Hern\u00e1ndez L, Rom\u00e1n Rodr\u00edguez L, Quintana-Gallego E, Carmona Bernal C, Alc\u00e1zar NB. The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient. Arch Bronconeumol. 2020;56(4):242\u20138.","journal-title":"Arch Bronconeumol"},{"issue":"5","key":"1785_CR129","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.arbres.2019.11.017","volume":"56","author":"A Ruano-Ravi\u00f1a","year":"2020","unstructured":"Ruano-Ravi\u00f1a A, Fern\u00e1ndez-Villar A, L\u00f3pez-Campos JL. Coping with low mortality and exacerbation rate differences between COPD triple therapy studies, and a proposal for upcoming studies. Arch Bronconeumol. 2020;56(5):336\u20138.","journal-title":"Arch Bronconeumol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01785-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01785-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01785-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T18:21:14Z","timestamp":1667326874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01785-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":129,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1785"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01785-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"20 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u251c\u00e1 degli Studi di Roma Tor Vergata within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Miguel \u00c1ngel Mart\u00ednez-Garc\u00eda, Grace Oscullo, Alberto Garc\u00eda-Ortega, Maria Gabriella Matera, Paola Rogliani, and Mario Cazzola have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"M\u00c1M-G and MC: Conceptualization, supervision, writing\u2014original draft, and writing\u2014review and editing. GO: Systematic clinical review of the literature, writing\u2014review and editing. AG-O: Systematic clinical review of the literature, writing\u2014review and editing. MGM: Validation, writing\u2014review and editing. PR: Validation, writing\u2014review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}